In the end, the FDA only approved the drug for a rare genetic condition with clearer data.
Source: Ars Technica
In the end, the FDA only approved the drug for a rare genetic condition with clearer data.
In the end, the FDA only approved the drug for a rare genetic condition with clearer data.
Source: Ars Technica
0 Comments
Sign in to join the conversation
No comments yet. Be the first!